Abstract
So-called "Philadelphia-positive acute leukaemias" require varied therapeutic management. Additional chromosome anomalies together with Ph1 indicate an acute transformation of a Philadelphia-positive disease, requiring "non-myelotoxic" treatment and new therapeutic approaches. By contrast, "de novo" acute leukaemias with a Ph1-positive karyotype should be treated with intensive chemotherapy for the induction and maintainance of remission.
Publication types
-
Case Reports
-
English Abstract
-
Review
MeSH terms
-
Acute Disease
-
Adult
-
Blood Transfusion
-
Chromosomes, Human, 21-22 and Y*
-
Cytarabine / therapeutic use
-
Female
-
Glucocorticoids / therapeutic use
-
Hematopoietic Stem Cells / ultrastructure
-
Humans
-
Leukapheresis
-
Leukemia / genetics*
-
Leukemia, Myeloid, Acute / genetics
-
Leukemia, Myeloid, Acute / therapy
-
Male
-
Middle Aged
-
Vincristine / therapeutic use
Substances
-
Glucocorticoids
-
Cytarabine
-
Vincristine